Invivyd Inc. Common Stock (IVVD)
Stock · NASDAQ · Health Care
$0.6212as of 10/16/2026
Price chart
Active signals
Revenue-Price Divergence (1Y+)63.6%Revenue-Price Divergence (6M)63.6%
High Beta20.7%
200 SMA Touch0.0%Resistance level
$0.808725
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
IVVD Signal Track Record
How signals performed across all stocks →What IVVD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -2.1% | 46% | September 17, 2026 |
| Bollinger Band Breakout | 24 | -5.9% | 33% | September 21, 2026 |
| Bollinger Band Breakdown | 19 | -12.2% | 26% | July 20, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -0.7% | 44% | April 22, 2026 |
| Any 20-session window (baseline) | -4.8% | 43% |
Computed by MarketWall from daily closing prices since May 20, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IVVD
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEM…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 122
- Website
- invivyd.com/
Fundamentals
- 1-day range
- $0.6143$0.6817
- Market cap
- $194.15M
- P/E (trailing)
- —
- P/E (forward)
- -1.22
- EPS (trailing)
- $-0.37
- Dividend yield
- —
- Beta
- 1.32
- Avg. volume
- 5.02M
52-week range
$0.5277$3.07
Next earnings: August 13, 2026 · EPS estimate $-0.14confirmed
How Invivyd Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Operating Income-$55.56M(-104%)
Forecasts
3 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$10
+1509.8%
Median
$10
+1509.8%
Low
$10
+1509.8%
Invivyd Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
- VYGRVoyager Therapeutics Inc. Common Stock$1.9▼ 7.77%Market cap $189.12MP/E —$2.33$5.55
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
- OTLKOutlook Therapeutics Inc. Common Stock$0.488▼ 2.40%Market cap $181.85MP/E —$0.1611$2.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
| VYGR Voyager Therapeutics Inc. Common Stock | $189.12M | — | $1.9 | ▼ 7.77% | $2.33$5.55 |
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
| OTLK Outlook Therapeutics Inc. Common Stock | $181.85M | — | $0.488 | ▼ 2.40% | $0.1611$2.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Invivyd And SPEAR Study Group Initiate FLINTLOCK Phase 2 Trial Evaluating Safety, Tolerability, Pharmacokinetics, And Clinical Efficacy Of High-Dose Monoclonal Antibody VYD2311 In Individuals With Long COVID Or Post-Vaccination Syndromebenzinga · 10/14/2026
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/5/2026
- Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated ApprovalYahoo · 10/5/2026
- Invivyd’s Covid-directed mAb hits Phase III safety goalsYahoo · 9/30/2026
- Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 AntibodyBenzinga · 9/29/2026
- Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval SubmissionYahoo · 9/29/2026
- Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission TranscriptSeekingAlpha · 9/29/2026
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311Yahoo · 9/29/2026
- Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - SlideshowSeekingAlpha · 9/29/2026
Insider Activity
Insider Actions →Acquired
11.17M
Disposed
228.0K
- Sheffield Ian · August 31, 2026 · Grant100.0K
- Elia Marc · August 30, 2026 · Grant10.70M
- Lee Timothy Edward · August 18, 2026 · Sale18.4K @ $0.8429
- Green Julie · August 18, 2026 · Sale18.4K @ $0.8429
- Andersen Jill · August 18, 2026 · Sale30.7K @ $0.8429
- Allen Robert D. III · August 18, 2026 · Sale17.0K @ $0.8429
- Duke William E. · August 18, 2026 · Sale18.4K @ $0.8429
- Lee Timothy Edward · August 17, 2026 · Sale22.4K @ $0.722
- Green Julie · August 17, 2026 · Sale22.4K @ $0.722
- Andersen Jill · August 17, 2026 · Sale37.3K @ $0.722
- Allen Robert D. III · August 17, 2026 · Sale20.7K @ $0.722
- Duke William E. · August 17, 2026 · Sale22.4K @ $0.722
- Lee Timothy Edward · August 15, 2026 · Option Exercise102.0K
- Green Julie · August 15, 2026 · Option Exercise102.0K
- Andersen Jill · August 15, 2026 · Option Exercise170.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 225.79M
- Total value held
- $291.47M
- Institutional holders
- 136
Top holders this quarter
- Unknown33.09M
- Unknown20.86M
- Unknown19.52M
- Unknown18.97M
- Unknown10.95M
- Unknown10.07M
- Unknown9.25M
- Unknown9.07M
- Unknown8.44M
- Unknown7.71M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
IVVD noted among health-care stocks moving on Monday
Invivyd (IVVD) was listed among twelve health-care stocks that showed price movement in Monday’s pre-market and intraday sessions, according to Benzinga. The mention reflects short-term trading activity but does not indicate a specific catalyst for the company.
IVVD noted among health-care stocks moving on Monday. Invivyd (IVVD) was listed among twelve health-care stocks that showed price movement in Monday’s pre-market and intraday sessions, according to Benzinga. The mention reflects short-term trading activity but does not indicate a specific catalyst for the company.